

COGS 209 Mini-Project Proposal

Lead author: Sierra Wilson

Co-authors: Dante Fisher, Clara Wolfe, Lora Khatib

Title: Development of a chemotyping strategy for consumer *Cannabis sativa*

Research Question

Cannabis is the third most commonly used substance worldwide with approximately 18% of Americans having used it at least once in their lifetime (Substance Abuse and Mental Health Services Administration, 2020). Out of these users, 10% report using cannabis for medical purposes (Compton et al., 2017). Cannabis has been approved for medicinal use by the US Food and Drug Administration (FDA) for various conditions such as chemotherapy-induced nausea, unattended weight loss caused by HIV, and for chronic pain management (Hill, 2019). However, research on *Cannabis sativa* has long lagged behind the boom in consumer access to cannabis. This may be influenced by the US Drug Enforcement Administration ruling cannabis a schedule I drug in the 1970s, increasing barriers to access the drug for many basic science laboratories. Additionally, until 2022, the only NIDA-approved government cannabis supplier was at the University of Mississippi (US Food and Drug Administration, 2023). This supply lacked the potent concentration of relevant cannabinoids that many Americans can find at their local dispensary, particularly as consumer trends push cannabis products' potencies to even higher levels than previous decades (Chandra et al., 2019).

Furthermore, it has been demonstrated *in vitro* that of the 200+ phytocannabinoids and terpenoids naturally found in cannabis, several interact with the endogenous cannabinoid receptors (Dvorakova et al., 2022; Straiker et al., 2021). Therefore, the various compounds found in cannabis may interact at the receptor and produce a synergistic "entourage effect" (Russo, 2011). Altogether, this evidence suggests that compounds other than Δ^9 -THC may contribute to the psychoactive and medicinal effects of cannabis. For example, cannabidiol (CBD) has recently been shown to exhibit anti-inflammatory, anti-epileptic, analgesic, and neuroprotective properties (Gonçalves, 2020). Currently, the cannabis industry standard is to classify strains by species (*indica*, *sativa*, *ruderalis*), but with widespread cultivation, genetic modifications, and unstandardized testing protocols, chemical makeup is relatively uncorrelated with species (Smith et al., 2022; Jikomes & Zoorob, 2018). Therefore, it would be more accurate and beneficial to the consumer to classify strains by chemical makeup alone.

Data/Materials.

We will use a publicly available cannabis chemical profile data set used in the article by Smith et al. (2022) entitled "The phytochemical diversity of commercial cannabis in the United States"

(<https://doi.org/10.1371/journal.pone.0267498>) maintained in a github-hosted csv located at: https://raw.githubusercontent.com/cjsmith015/phytochemical-diversity-cannabis/main/data/processed_lab_data_public_20220218.csv

We have decided to compare ratios of cannabinoids and terpenes between samples rather than their absolute masses in order to account for variation due to product type (i.e. flower product vs concentrate product).

Course impact/relevance.

In order to create meaningful, chemically informed categories with which to classify cannabis, we will perform a cluster analysis after using dimensionality reduction on the normalized data set. Once our data has been assigned to clusters, a classifier could be trained and tested on separate subsets of the data to determine which chemical constituents are most important for categorizing cannabis.

Outcomes.

One result of the analysis will be a set of cannabis categories based on chemical similarity. Clusters can be further characterized through analysis of the means and variances of the cannabinoid and terpenoid profiles of the strains that comprise them. Another potential result is a classifier capable of categorizing new strains into the newly generated categories.

References.

Chandra, S., Radwan, M. M., Majumdar, C. G., Church, J. C., Freeman, T. P., & ElSohly, M. A. (2019). New trends in cannabis potency in USA and Europe during the last decade (2008-2017). *European Archives of Psychiatry and Clinical Neuroscience*, 269(1), 5–15. <https://doi.org/10.1007/s00406-019-00983-5>

Compton, W.M., Han, B., Hughes, A., Jones, C.M. & Blanco, C. (2017). Use of marijuana for medical purposes among adults in the United States. *JAMA*, 317(2), 209-211. doi:10.1001/jama.2016.18900

Dvorakova, M., Wilson, S., Corey, W., Billingsley, J., Zimmowitch, A., Tracey, J., ... & Mackie, K. (2022). A critical evaluation of terpenoid signaling at cannabinoid CB1 receptors in a neuronal model. *Molecules*, 27(17), 5655.

Gonçalves, E. C., Baldasso, G. M., Bicca, M. A., Paes, R. S., Capasso, R., & Dutra, R. C. (2020). Terpenoids, cannabimimetic ligands, beyond the cannabis plant. *Molecules*, 25(7), 1567.

Hill, K. P. (2019). Medical use of cannabis in 2019. *JAMA*, 322(10), 974-975.

Jikomes, N., & Zoorob, M. (2018). The Cannabinoid Content of Legal Cannabis in Washington State Varies Systematically Across Testing Facilities and Popular Consumer Products. *Scientific Reports*, 8(1), Article 1. <https://doi.org/10.1038/s41598-018-22755-2>

Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *British Journal of Pharmacology*, 163(7), 1344-1364.

Smith, C. J., Vergara, D., Keegan, B., & Jikomes, N. (2022). The phytochemical diversity of commercial Cannabis in the United States. *PLOS ONE*, 17(5), e0267498. <https://doi.org/10.1371/journal.pone.0267498>

Straiker, A., Wilson, S., Corey, W., Dvorakova, M., Bosquez, T., Tracey, J., ... & Mackie, K. (2021). An evaluation of understudied phytocannabinoids and their effects in two neuronal models. *Molecules*, 26(17), 5352

Substance Abuse and Mental Health Services Administration/Center for Behavioral Health Statistics and Quality. (2020). *Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health*.

US Food and Drug Administration/Center for Drug Evaluation and Research. (2023). *Cannabis and cannabis-derived compounds: Quality considerations for clinical research*. <https://www.fda.gov/media/164690/download>